CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞，首个药物细胞疗法
英文原题：CAR-T cells, the first pharmaceutical cell therapy.
查看英文原题
CAR-T cells, the first pharmaceutical cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
21 世纪第二个十年中，血液系统恶性肿瘤的基因工程过继性细胞疗法取得成功，令免疫学家和肿瘤学家都感到惊讶。这一进展挑战了我们对个体化医疗作用、细胞产品与药物之间界限，以及免疫系统清除癌症能力局限的许多既有认识。此外，仍有许多挑战有待解决：该疗法价格昂贵、具有风险，且主要限于淋巴增殖性疾病。
展开英文摘要原文
The success of genetically engineered adoptive cell therapies in haematological malignancy in the second decade of the 21st century has surprised both immunologists and oncologists. It challenges much of our understanding of the role of personalised medicine, the divide between cell products and pharmaceutical drugs and the limitations of the immune system to clear cancer.
Furthermore, many challenges remain, the therapy is both expensive, hazardous and largely restricted to lymphoproliferative disease.
论文信息
- 作者
- Laurence A
- 单位
- UCL Hospitals NHS Trust, United Kingdom. Electronic address: arian.laurence@nhs.net.United Kingdom
- 文献类型
- 综述
- 期刊
- Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis2023 Oct
- 原文标识
- PubMed 37423868 · DOI 10.1016/j.transci.2023.103754